vs
ADMA BIOLOGICS, INC.（ADMA）与Rapid7, Inc.（RPD）财务数据对比。点击上方公司名可切换其他公司
Rapid7, Inc.的季度营收约是ADMA BIOLOGICS, INC.的1.6倍（$217.4M vs $139.2M），ADMA BIOLOGICS, INC.净利率更高（35.5% vs 1.4%，领先34.0%），ADMA BIOLOGICS, INC.同比增速更快（18.4% vs 0.5%），Rapid7, Inc.自由现金流更多（$36.4M vs $34.6M），过去两年ADMA BIOLOGICS, INC.的营收复合增速更高（30.4% vs 3.0%）
ADMA生物制剂公司是一家专注于研发、生产及商业化特种血浆来源免疫球蛋白疗法的生物制药企业，主要面向美国市场，为原发性免疫缺陷及其他免疫相关疾病患者、医护人员和医疗机构提供免疫健康领域的治疗方案。
Rapid7是全球领先的网络安全企业，提供漏洞管理、威胁检测与响应、云安全、安全分析等全系列安全解决方案，服务全球科技、医疗、金融、制造等行业的各类规模企业及公共部门客户，助力客户高效识别、应对和缓解网络安全风险。
ADMA vs RPD — 直观对比
营收规模更大
RPD
是对方的1.6倍
$139.2M
营收增速更快
ADMA
高出17.9%
0.5%
净利率更高
ADMA
高出34.0%
1.4%
自由现金流更多
RPD
多$1.9M
$34.6M
两年增速更快
ADMA
近两年复合增速
3.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $139.2M | $217.4M |
| 净利润 | $49.4M | $3.1M |
| 毛利率 | 63.8% | 68.9% |
| 营业利润率 | 45.1% | 1.0% |
| 净利率 | 35.5% | 1.4% |
| 营收同比 | 18.4% | 0.5% |
| 净利润同比 | -55.9% | 44.1% |
| 每股收益（稀释后） | $0.20 | $0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADMARPD
| Q4 25 | $139.2M | $217.4M | ||
| Q3 25 | $134.2M | $218.0M | ||
| Q2 25 | $122.0M | $214.2M | ||
| Q1 25 | $114.8M | $210.3M | ||
| Q4 24 | $117.5M | $216.3M | ||
| Q3 24 | $119.8M | $214.7M | ||
| Q2 24 | $107.2M | $208.0M | ||
| Q1 24 | $81.9M | $205.1M |
净利润ADMARPD
| Q4 25 | $49.4M | $3.1M | ||
| Q3 25 | $36.4M | $9.8M | ||
| Q2 25 | $34.2M | $8.3M | ||
| Q1 25 | $26.9M | $2.1M | ||
| Q4 24 | $111.9M | $2.2M | ||
| Q3 24 | $35.9M | $15.4M | ||
| Q2 24 | $32.1M | $6.5M | ||
| Q1 24 | $17.8M | $1.4M |
毛利率ADMARPD
| Q4 25 | 63.8% | 68.9% | ||
| Q3 25 | 56.3% | 70.2% | ||
| Q2 25 | 55.1% | 70.6% | ||
| Q1 25 | 53.2% | 71.7% | ||
| Q4 24 | 53.9% | 69.5% | ||
| Q3 24 | 49.8% | 70.6% | ||
| Q2 24 | 53.6% | 70.7% | ||
| Q1 24 | 47.8% | 70.3% |
营业利润率ADMARPD
| Q4 25 | 45.1% | 1.0% | ||
| Q3 25 | 38.0% | 2.7% | ||
| Q2 25 | 35.1% | 1.6% | ||
| Q1 25 | 30.4% | -0.0% | ||
| Q4 24 | 32.6% | 3.4% | ||
| Q3 24 | 33.1% | 6.0% | ||
| Q2 24 | 36.6% | 2.5% | ||
| Q1 24 | 26.7% | 4.7% |
净利率ADMARPD
| Q4 25 | 35.5% | 1.4% | ||
| Q3 25 | 27.1% | 4.5% | ||
| Q2 25 | 28.1% | 3.9% | ||
| Q1 25 | 23.4% | 1.0% | ||
| Q4 24 | 95.2% | 1.0% | ||
| Q3 24 | 30.0% | 7.2% | ||
| Q2 24 | 29.9% | 3.1% | ||
| Q1 24 | 21.7% | 0.7% |
每股收益（稀释后）ADMARPD
| Q4 25 | $0.20 | $0.05 | ||
| Q3 25 | $0.15 | $0.15 | ||
| Q2 25 | $0.14 | $0.13 | ||
| Q1 25 | $0.11 | $0.03 | ||
| Q4 24 | $0.45 | $0.08 | ||
| Q3 24 | $0.15 | $0.21 | ||
| Q2 24 | $0.13 | $0.09 | ||
| Q1 24 | $0.08 | $0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $87.6M | $474.7M |
| 总债务越低越好 | $72.1M | — |
| 股东权益账面价值 | $477.3M | $154.7M |
| 总资产 | $624.2M | $1.7B |
| 负债/权益比越低杠杆越低 | 0.15× | — |
8季度趋势，按日历期对齐
现金及短期投资ADMARPD
| Q4 25 | $87.6M | $474.7M | ||
| Q3 25 | $61.4M | $407.1M | ||
| Q2 25 | $90.3M | $511.7M | ||
| Q1 25 | $71.6M | $493.5M | ||
| Q4 24 | $103.1M | $521.7M | ||
| Q3 24 | $86.7M | $443.7M | ||
| Q2 24 | $88.2M | $442.6M | ||
| Q1 24 | $45.3M | $411.7M |
总债务ADMARPD
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ADMARPD
| Q4 25 | $477.3M | $154.7M | ||
| Q3 25 | $431.2M | $127.2M | ||
| Q2 25 | $398.3M | $90.4M | ||
| Q1 25 | $373.4M | $52.7M | ||
| Q4 24 | $349.0M | $17.7M | ||
| Q3 24 | $231.9M | $-5.1M | ||
| Q2 24 | $188.3M | $-52.6M | ||
| Q1 24 | $153.7M | $-86.4M |
总资产ADMARPD
| Q4 25 | $624.2M | $1.7B | ||
| Q3 25 | $568.7M | $1.7B | ||
| Q2 25 | $558.4M | $1.6B | ||
| Q1 25 | $510.6M | $1.6B | ||
| Q4 24 | $488.7M | $1.7B | ||
| Q3 24 | $390.6M | $1.6B | ||
| Q2 24 | $376.4M | $1.5B | ||
| Q1 24 | $350.9M | $1.5B |
负债/权益比ADMARPD
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $35.6M | $37.6M |
| 自由现金流经营现金流 - 资本支出 | $34.6M | $36.4M |
| 自由现金流率自由现金流/营收 | 24.8% | 16.8% |
| 资本支出强度资本支出/营收 | 0.8% | 0.5% |
| 现金转化率经营现金流/净利润 | 0.72× | 12.01× |
| 过去12个月自由现金流最近4个季度 | $27.8M | $146.2M |
8季度趋势，按日历期对齐
经营现金流ADMARPD
| Q4 25 | $35.6M | $37.6M | ||
| Q3 25 | $13.3M | $39.0M | ||
| Q2 25 | $21.1M | $47.5M | ||
| Q1 25 | $-19.7M | $29.8M | ||
| Q4 24 | $50.2M | $63.8M | ||
| Q3 24 | $25.0M | $44.0M | ||
| Q2 24 | $45.6M | $32.9M | ||
| Q1 24 | $-2.2M | $31.1M |
自由现金流ADMARPD
| Q4 25 | $34.6M | $36.4M | ||
| Q3 25 | $-1.1M | $34.8M | ||
| Q2 25 | $18.7M | $46.6M | ||
| Q1 25 | $-24.4M | $28.4M | ||
| Q4 24 | $47.5M | $62.6M | ||
| Q3 24 | $24.0M | $42.6M | ||
| Q2 24 | $43.6M | $32.6M | ||
| Q1 24 | $-4.6M | $30.4M |
自由现金流率ADMARPD
| Q4 25 | 24.8% | 16.8% | ||
| Q3 25 | -0.8% | 16.0% | ||
| Q2 25 | 15.3% | 21.8% | ||
| Q1 25 | -21.2% | 13.5% | ||
| Q4 24 | 40.4% | 28.9% | ||
| Q3 24 | 20.0% | 19.9% | ||
| Q2 24 | 40.7% | 15.7% | ||
| Q1 24 | -5.6% | 14.8% |
资本支出强度ADMARPD
| Q4 25 | 0.8% | 0.5% | ||
| Q3 25 | 10.7% | 1.9% | ||
| Q2 25 | 2.0% | 0.4% | ||
| Q1 25 | 4.1% | 0.6% | ||
| Q4 24 | 2.3% | 0.5% | ||
| Q3 24 | 0.9% | 0.6% | ||
| Q2 24 | 1.9% | 0.1% | ||
| Q1 24 | 2.9% | 0.3% |
现金转化率ADMARPD
| Q4 25 | 0.72× | 12.01× | ||
| Q3 25 | 0.36× | 3.97× | ||
| Q2 25 | 0.62× | 5.70× | ||
| Q1 25 | -0.73× | 14.14× | ||
| Q4 24 | 0.45× | 29.36× | ||
| Q3 24 | 0.70× | 2.85× | ||
| Q2 24 | 1.42× | 5.03× | ||
| Q1 24 | -0.12× | 22.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
RPD
| Products | $209.1M | 96% |
| Services | $8.2M | 4% |
